Analysts anticipate Rhythm Pharmaceuticals to report an earnings per share (EPS) of $-0.81.
The announcement from Rhythm Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
The company's EPS beat by $0.16 in the last quarter, leading to a 1.09% drop in the share price on the following day.
Here's a look at Rhythm Pharmaceuticals's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-0.71
-2.16
-0.7
-0.76
EPS Actual
-0.55
-2.35
-0.7
-0.76
Price Change %
-1.0%
-1.0%
2.0%
2.0%
Stock Performance
Shares of Rhythm Pharmaceuticals were trading at $49.01 as of November 01. Over the last 52-week period, shares are up 94.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analysts' Take on Rhythm Pharmaceuticals
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Rhythm Pharmaceuticals.
With 8 analyst ratings, Rhythm Pharmaceuticals has a consensus rating of Buy. The average one-year price target is $61.0, indicating a potential 24.46% upside.
Peer Ratings Comparison
The below comparison of the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Amicus ...
